Absci Corp cash flow statement
In fiscal 2025, Absci Corp's operations generated −$92.9m of cash; it spent $1.1m on capital projects, leaving free cash flow of −$94.0m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −11 | −61 | −81 | −65 | −72 | −93 | −108 |
| Depreciation and amortisation | 1 | 7 | 13 | 14 | 13 | 12 | 11 |
| Stock-based pay | 0 | 11 | 13 | 11 | 19 | 18 | 18 |
| Capital spending | 2 | 38 | 16 | 1 | 0 | 1 | 1 |
| Free cash flow | −13 | −99 | −98 | −65 | −73 | −94 | −109 |
| Free cash flow after stock pay | −14 | −109 | −110 | −77 | −92 | −112 | −127 |
| Shares issued | 0 | 210 | 1 | 1 | 82 | 106 | 170 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −21 | −17 | −22 | −17 | −25 | −29 | −26 | −28 |
| Depreciation and amortisation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Stock-based pay | 6 | 5 | 5 | 5 | 4 | 4 | 4 | 5 |
| Capital spending | 0 | 0 | 0 | 0 | 1 | −0 | 0 | 0 |
| Free cash flow | −21 | −17 | −22 | −17 | −26 | −29 | −26 | −28 |
| Free cash flow after stock pay | −26 | −22 | −27 | −22 | −30 | −33 | −31 | −33 |
| Shares issued | 1 | −2 | 42 | 0 | 61 | 3 | 8 | 98 |
Compare with peers
- Ovid Therapeutics Inc. cash flow
- Cartesian Therapeutics, Inc. cash flow
- Dare Bioscience, Inc. cash flow
- Seres Therapeutics, Inc. cash flow
- Korsana Biosciences, Inc. cash flow
Head to head: ABSI vs OVIDABSI vs RNACABSI vs DAREABSI vs MCRB
More: Biotechnology stocks compared, Health Care sector, rankings of US companies